Form 4: Ionis Pharma EVP Birchler Sells Shares After PRSU Vesting

Ionis Pharmaceuticals EVP Brian Birchler acquired shares from performance-based vesting and subsequently sold a portion of his common stock holdings.

Summary

• Brian Birchler, EVP, Corporate and Development Operations at Ionis Pharmaceuticals, Inc. (IONS), reported changes in his beneficial ownership.
• On January 29, 2026, Birchler acquired 11,991 shares of common stock at $0.0 upon the vesting of performance-based restricted stock units (PRSUs).
• The PRSUs vested at 167.27% of target shares, indicating strong achievement of pre-established performance goals based on the Issuer's relative total shareholder return compared to a peer group.
• Following the acquisition, Birchler's direct beneficial ownership was 72,426 shares.
• On January 30, 2026, Birchler sold 6,179 shares of common stock at a weighted average price of $83.0309 per share.
• The sales occurred in multiple transactions with prices ranging from $83.00 to $83.08.
• After the sale, Birchler's direct beneficial ownership stands at 66,247 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the strong performance-based vesting of executive compensation, which reflects favorable relative shareholder return, despite the routine partial sale of shares.

Positives

• Performance-based restricted stock units (PRSUs) vested at 167.27% of target, indicating strong achievement of performance goals.
• The performance goal was based on the Issuer's relative total shareholder return compared to a peer group, suggesting strong relative company performance.

Negatives

• An executive officer sold a portion of their common stock holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the high vesting percentage of 167.27% for performance-based restricted stock units, tied to relative total shareholder return against a peer group, suggests Ionis Pharmaceuticals has outperformed its industry peers in terms of shareholder value creation over the performance period.

Comparison to Industry Standards

• The 167.27% vesting of PRSUs, based on relative total shareholder return, indicates that Ionis Pharmaceuticals' performance exceeded the median or average of its defined peer group, which typically includes other biotechnology or pharmaceutical companies of similar size and market focus.
• This level of outperformance in shareholder return is a strong indicator of effective strategic execution and market perception compared to industry benchmarks.

Stakeholder Impact

• Shareholders: The high vesting percentage of PRSUs suggests strong company performance relative to peers, which is generally positive for shareholder value.
• Executive Management: Brian Birchler's compensation is directly tied to company performance, aligning executive interests with shareholder interests.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, PRSU, Executive Compensation, Brian Birchler, Shareholder Return